cellNUA is a biotechnology company transforming how the world approaches infectious disease, immune dysfunction, and cellular regeneration—by unlocking the therapeutic intelligence of nature itself. Founded in Galway, Ireland, with a growing international presence, cellNUA merges evolutionary biology, nanomedicine, and advanced bioinformatics to create naturally inspired, scientifically validated interventions. At its core is a belief that the cell is not a passive victim of disease, but an active architect of its own defense. Our goal is to decode the biochemical logic that governs this cellular resilience and translate it into scalable healthcare platforms. Our flagship platform, BEEMAR™, is the first immune system technology built on comparative glyco-genomics between honeybees and humans. It harnesses the honeybee’s highly evolved immune response—one that is faster than human immunity and uniquely precise—alongside regenerative compounds from marine ecosystems. Through proprietary inoculation and extraction protocols, BEEMAR™ produces pathogen-specific biologics that target viruses, bacteria, and parasites without relying on traditional synthetic drugs. Preclinical trials have shown remarkable reductions in viral load—including against COVID-19, polio, and herpes—and significant inhibition of the malaria parasite, all with no observed cytotoxicity. Supporting platforms like CellMar78™ and Occunase™ extend our approach from therapeutic to preventative medicine. CellMar78™ is a marine-derived, isotonic delivery medium designed for safe gene therapy, stem cell support, and regenerative research. Occunase™, a drug-free nasal spray, forms a mechanical barrier in the nasal mucosa to block respiratory pathogens and allergens—a practical, immune-independent defense for public health. cellNUA’s research is rooted in deep omics analysis, high-throughput screening, and a platform-based architecture that allows rapid adaptation to emerging threats. Our partnerships with institutions such as Johns Hopkins University and Trinity College Dublin, as well as preclinical validations in Europe and Africa, reinforce our commitment to rigorous science and global health equity. With a vision to localize biotech solutions through decentralized “BioCities,” beginning in Europe and the Middle East, we aim to reduce global dependence on imported therapeutics and empower regions with rapid-response health infrastructure. Our work is not only about treatments—it is about restoring trust in biology’s original intelligence and equipping humanity with systems that are proactive, precise, and profoundly sustainable. cellNUA: Where Nature’s Intelligence Becomes the Blueprint for Modern Medicine.
Cellerate Limited
Cellerate makes lab equipment for automating common processes in battery research, like coin cell and pouch cell assembly, materials handling, and quality control. Our systems are designed to save time, improve consistency, and reduce manual workload in both academic and industrial labs. We help battery researchers focus on the science, not the repetition, by streamlining lab workflows and improving data quality.
Celestia Diagnostics
Celestia Diagnostics develops lab tests and clinical bioinformatics systems to aid in the diagnosis and treatment of chronic complex conditions such as Long COVID, ME/CFS, and POTS.
Celaid Therapeutics Inc.
Celaid Therapeutics Inc. is developing an allogeneic hematopoietic stem cell (HSC) therapy for hematological diseases in the United States, with both an IND filing and initiation of a Phase 1/2 clinical study planned for 2027. Originating from the University of Tokyo and the University of Tsukuba, Celaid is a biotechnology startup with proprietary technology for the selective ex vivo expansion of HSCs. By enabling safe, efficient, and scalable expansion of human HSCs, Celaid aims to advance next-generation cell and gene therapies, including treatments for hematologic and genetic diseases, ex vivo HSC gene therapies, and angiogenesis-based therapies for ischemic conditions. [Company’s Conference Objectives] Celaid Therapeutics has two primary objectives: (1) to out-license its lead asset, CLD-001, to global pharma and biotech companies, and (2) to license its proprietary HSC expansion technology to CDMOs and pharma partners.______________________ (1) CLD-001 is an HSC therapy for non-malignant diseases (U.S. IND planned in 2027) that addresses key HSCT limitations—such as donor scarcity and HLA mismatch—by leveraging cord blood and proprietary expansion technology to deliver optimally matched, engraftable HSCs. (2) In parallel, Celaid is pursuing technology licensing and strategic collaborations, focusing on applications in iPSC-derived HSC expansion, ex vivo HSC gene therapy, and scalable manufacturing of blood and immune cell therapeutics, supported by joint research with global CDMO and pharma partners. [Lead asset pipeline, CLD-001] CLD-001 is being developed as a hematopoietic stem cell (HSC) therapy for hematological diseases, with an Investigational New Drug (IND) application planned in the United States in 2027. The program targets non-malignant diseases, addressing a significant unmet need in curative treatment options. Rare blood disorders – including aplastic anemia, primary immunodeficiencies, inherited metabolic disorders, and sickle cell disease – typically present in childhood and are associated with severe physical and neurological complications, leading to poor long-term prognosis. At present, the only curative treatment is allogeneic hematopoietic stem cell transplantation (HSCT). However, substantial limitations remain, including donor scarcity, HLA mismatch, transplant-related mortality, and complications such as graft-versus-host disease (GvHD). CLD-001 is designed to overcome these challenges. By utilizing cryopreserved cord blood from established cord blood banks, the therapy addresses donor availability constraints. Furthermore, proprietary HSC expansion technology resolves the inherent limitation of low stem cell counts in cord blood, enabling the generation of sufficient cell doses for transplantation. This approach allows for the selection and provision of optimally HLA-matched HSCs tailored to individual patients. Through these innovations, CLD-001 aims to deliver HLA best-matched, bone marrow–engrafting HSCs, with the potential to significantly improve engraftment outcomes and overall survival in patients undergoing HSC therapy. [Technology License activities] Celaid is also advancing technology license-out activities, positioning its platform for adoption by biotech companies, CDMOs, and pharmaceutical partners. Celaid has also been actively engaged in collaborative research with CDMOs and pharma companies across the U.S., Europe, and Japan, generating early commercial validation and demonstrating the platform’s ability to address partner-specific manufacturing challenges—particularly in iPSC-derived HSC expansion, ex vivo HSC gene therapy manufacturing, and the scalable production of blood and immune cell–based therapeutics.
Ceidos
Bioproduction is complex particularly during cell expansion in bioreactors. Current methods to assess the viability, density and shape of mammalian cells are highly manual and require recurrent sampling. The C-Netics enables non-destructive and label-free analysis in real time. It works coupled to a dedicated single use kit that integrates an analysis cassette with high-end microelectronic sensors. The monitoring can then be run automatically during the entire duration of the cell culture.This allows the detection of anomalies in real-time and can also be used to quickly optimize a process development. | Ceidos offers an automatic laboratory device that improves the biopharmaceutical production process. Faced with the challenge of slow, manual control of cell cultures, Ceidos introduces the C-Netics, a sophisticated device compatible with most bioreactors. It enables automated, real-time cell culture analysis with a single-use kit, increasing efficiency, reducing contamination and guaranteeing high-quality results, revolutionizing laboratory work and setting new standards in the field of biotechnology. Ceidos SA is a pioneering biotechnology company based in Monthey, Switzerland and founded in 2019. Specializing in the development of innovative solutions for the biopharmaceutical industry, Ceidos is expert in advanced technologies such as microscopy, microelectronics, and machine learning allowing the development of breakthrough bioprocessing devices. | Ceidos aims to revolutionize biopharmaceutical production with C-Netics, an advanced system for real-time, non-destructive cell culture monitoring. By integrating microscopy, dielectrophoresis, and AI-driven analysis, C-Netics ensures precise control of cell viability, density, and culture conditions. Unlike traditional methods, it connects directly to bioreactors, minimizing contamination risks and reducing manual interventions. Ceidos collaborates with industry leaders and CMOs/CDMOs to optimize bioprocesses, enhance efficiency, and improve the scalability of advanced therapies like CAR-T and monoclonal antibodies.
CdmoGen
A one-stop CTDMO, CdmoGen Co., Ltd. offers comprehensive and integrated contract services spanning the full length of the cell and gene therapy development process. From early optimization to the GMP and non-GMP manufacture of virus vector- and mRNA-based therapeutics, through CMC support and a robust panel of quality analyses, including lot release testing, CdmoGen is a full-service partner providing reliable and efficient developmental support. Recognized as the first GMP-compliant manufacturer approved by the Ministry of Food and Drug Safety (Republic of Korea), CdmoGen is also ISO17025-accredited, and has successfully completed over 250 GMP manufacturing and QC testing projects involving virus vector-based gene therapeutics and vaccines since 2016. In addition to continually working to increase its custom service capabilities, including validation studies and process, assay, and SOP development, CdmoGen brought online in 2023 a custom-built facility dedicated to the manufacture and testing of mRNA vaccines to further expand its service offerings. Virus seed stock and cell banking will also take place in this facility. Since its inception, CdmoGen has, through its experiences, expanded its knowledge base while establishing a track record for success, with a CTDMO customer having recently been approved for a clinical trial by the FDA. Moving forward, CdmoGen will do all it can to provide every partner with the support they need to achieve their own successes in the development of biopharmaceuticals and cell and gene therapeutics. | CdmoGen Co., Ltd. is a gene therapy new drug development company specializing in therapeutics for ocular diseases that also offers one-stop, full-service CTDMO services for virus vector- and mRNA technology-based biopharmaceuticals.
CBCC Global Research
We are a full service Clinical CRO based in California with office in India and supporting global bio-pharmaceutical and medical device companies. We offer clinical development services for NCE molecules, 505(b)2 and complex generics products requiring patient based clinical studies as part of ANDA/NDA submission. | We are a comprehensive Clinical Contract Research Organization (CRO) headquartered in California, with an additional office in India, providing support to global biopharmaceutical and medical device firms. Our services encompass clinical development for New Chemical Entity (NCE) molecules, 505(b)(2) pathways, and intricate generic products necessitating patient-centric clinical trials as components of ANDA/NDA submissions. Furthermore, we cater to pharmaceutical companies, assisting them with regulatory necessities for both pre-Investigational New Drug (pre-IND) and Investigational New Drug (IND) submissions. | Founded in 2010, CBCC Global Research is a highly regarded full-service clinical CRO, with expertise in innovator, specialty generics, biosimilar and regulatory pathways, across several core therapeutic areas. CBCC provides a suite of high-quality services across multiple mission-critical, specialized functions, including Clinical Operations, Site management, Patient recruitment, biometrics, regulatory services, and scientific and medical writing, for a wide range of study types for the US, India, and Australia execution.
CatchPad
Combines interactive training hardware with AI powered software to deliver professional grade performance tracking across sports, health, education, and entertainment sectors. Deployed in 40+ countries, we provide real time analytics, digital coaching, and talent identification. Actively seeking distributor partnerships globally.
Catalyst by Cordica Medical
Catalyst by Cordica Medical (formerly TAG3) brings together multidisiplinary teams – industrial designers, biomedical engineers, and manufacturing experts – to ensure innovation and manufacturability evolve in tandem. From concept to exploration to clinical validation, Catalyst helps OEMs move faster, smarter and with total confidence in their final decision. Visit https://www.cordicamedical.com/ or email info@cordicamedical.com.
Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first and is committed to empowering healthcare providers and patients with the goal of improved health outcomes. Primarily focused on dermatologic cancers and gastroenterological disease, Castle’s innovative tests are designed to help answer critical clinical questions and address treatment plan challenges facing clinicians to better inform patient care decisions. Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Using its expertise in advanced technologies, such as genomics, spatialomics, data analytics and artificial intelligence, Castle digs deep into treatment pathways to develop personalized, clinically actionable tests that can improve, and potentially transform, the management of diseases and patient outcomes. | At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.